Johnson & Johnson Completes $3.05 Billion Acquisition of Halda Therapeutics to Strengthen Oncology Pipeline
Johnson & Johnson Completes $3.05 Billion Acquisition of Halda Therapeutics to Strengthen Oncology Pipeline Source :- MSN Johnson & Johnson has bought Halda Therapeutics OpCo, Inc., a biotechnology company in the clinical stage that focuses on making targeted cancer treatments. The deal was worth $3.05 billion in cash. The deal greatly expands Johnson & Johnson's oncology portfolio and shows that the company is committed to improving precision-based cancer treatments over the long term. The Regulated Induced Proximity Targeting Chimera, or RIPTAC™, platform is what Halda Therapeutics is most famous for. The technology is meant to make oral, targeted therapies that can kill cancer cells without hurting healthy tissue. The platform has worked on a number of solid tumors, such as prostate, breast, and lung cancers. Johnson & Johnson now fully owns HLD-0915, Halda's most important clinical-stage asset for prostate cancer. The treatment is an oral pill taken once ...